Submit a comment
Citation Information: J Clin Invest. 1976;57(4):1000-1008. https://doi.org/10.1172/JCI108341.
Abstract
The syncytiotrophoblastic cells of the human placenta contain a cytoplasmic protein recognized by fluorescein-labeled transcortin-specific antibody. Purification of this protein from human placenta, by those methods employed for the purification of human plasma transcortin, yielded a protein that exhibited antigenic and biochemical similarity to plasma transcortin. Placental transcortin differs from plasma transcortin in that it has a smaller sedimentation coefficient (3S vs 3.75S) and binds cortisol less strongly. This purified protein is able to block the phytohemagglutinin response of maternal lymphocytes even more than serum transcortin. It is postulated that the biological role may be that of inhibiting the maternal cell-mediated immune response to the presence of the antigenic conceptus.
Authors
S Werthamer, S Govindaraj, L Amaral
Guidelines
The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.
- Comments appear on the Journal’s website and are linked from the original article’s web page.
- Authors are notified by email if their comments are posted.
- The Journal reserves the right to edit comments for length and clarity.
- No appeals will be considered.
- Comments are not indexed in PubMed.
Specific requirements
- Maximum length, 400 words
- Entered as plain text or HTML
- Author’s name and email address, to be posted with the comment
- Declaration of all potential conflicts of interest (even if these are not ultimately posted); see the Journal’s conflict-of-interest policy
- Comments may not include figures
Copyright © 2024 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)